ASTRAZENECA

AstraZeneca is UK Based Pharmaceutical and Bio-Technology Company. They have done some advanced research on Oncology. In the fight against COVID-19, Astrazeneca is one among World Top 5 Companies which has done advanced phase of Covid-19 testing in collaboration with the University of Oxford and are launching Phase III trials. Headquarters is in UK.

AstraZeneca Product Sales split by Disease Area for year ending Dec-2021

Oncology contributed 36% and annual revenue contributed is 13,048 million USD.
BioPharmaceuticals contributed 38% and annual revenue contributed is 8,02 million USD.
Rare Disease contributed 8% annual revenue contributed is 3,070 million USD.
Other Medicines contributed 17% annual revenue contributed is 2,367 million USD.
Covid-19 contributed 11% annual revenue contributed is 4,002 million USD.
Respiratory & Immunology contributed 17% annual revenue contributed is 6,034 million USD.

Facts About Company

AstraZeneca annual revenue was 44,351 million USD for year ending Dec-2022 and annual operating profit was 3,757 million USD and annual net income was 3,288 million USD for year ending Dec-2022.

AstraZeneca has 83,500 employees as on 2022 when compared to with 76,100 employees as on 2020 and 70,600 employees as on 2019.

AstraZeneca has total assets of 96,483 million USD as on Dec-2022 when compared to 66,729 million USD as on Dec-2020.

AstraZeneca Product Sales split of 44,351 Million USD by Disease Area for year ending Dec-2022

11,745 Million USD from Emerging Markets (Previous year 12,281 million USD)
17,920 Million USD from USA. (Previous year 2021 : 12,228 million USD)
8,738 Million USD from Europe. (Previous year 2021 : 8,050 million USD)
From the rest of the World, it is 5,948 Million USD (Previous year 2021 : 4,858 million USD)

As on December-2022, Astrazeneca has 83,500 employees and out of that

16,500 employees are from USA.
10,700 employees are from UK
16,500 employees are from China
7,100 employees are from Sweden
11,400 employees are from Other Europe has
7,200 employees are from Other Asia Pacific
1,200 employees are from Canada and 2,400 employees are from Middle East and Africa and 2,000 employees are from Russia and 3,500 employees are from Japan and 1,000 employees are from Australia and New Zealand.

Astrazeneca company acquired Alexion Pharmaceuticals for 39 Billion USD in 2020.

Founded Year

1999

Annual Results Summary:

AstraZeneca PLC - Annual Results - Revenue and Net Profit - in Million USD:

Year - Ending	Revenue	Operating Income	Net Profit
Dec-2022	44,351	3,757	3,288
Dec-2021	37,417	1,056	112
Dec-2020	26,217	5,162	3,196
Dec-2019	24,384	1,702	1,335
Dec-2018	22,090	1,510	2,155
Dec-2017	22,465	2,292	3,001

Balance Sheet Summary

AstraZeneca PLC - Balance Sheet Summary - in Million USD:

Astrazeneca Total Assets as on Dec-2022 was 96,483 Million USD.

Astrazeneca Total Liabilities as on Dec-2022 was 59,425 Million USD.

Astrazeneca Total Equity as on Dec-2022 was 37,058 Million USD.

Quarterly Results Summary:

AstraZeneca PLC - Quarterly Results - Revenue and Net Profit - in Million USD:

Quarter - Ending	Revenue	Net Profit
Jun-2023	11,416	1,818
Mar-2023	10,879	1,803
Dec-2022	11,207	901
Sep-2022	10,982	1,640
Jun-2022	10,771	360
Mar-2022	11,390	386
Dec-2021	12,011	-292 (Loss)
Sep-2021	9,866	-1,652
Jun-2021	8,220	550
Mar-2021	7,320	1,561
Dec-2020	7,410	1,012
Sep-2020	6,578	651
Jun-2020	6,275	837
Mar-2020	6,354	780
Dec-2019	6,664	313
Sep-2019	6,406	299
Jun-2019	5,823	130
Mar-2019	5,491	593

Comments

Oxford Vaccine Trials again resumed by Astrazeneca

Oxford Vaccine Trials again resumed by Astrazeneca after UK Regulatory Authorities had given permission to go ahead with trials. Post one person undergoing trials had fallen ill, Astrazeneca temporarily paused trials of Oxford Vaccine.

Then again after review, as UK health regulatory authorities had given permission to go ahead with trials, again Oxford Vaccine Trials started.

Russia vaccine and Oxford vaccine are two vaccines related to Covid-19, that are in most advance stages of testing.

Sun, 13/09/2020 - 14:51